Andere Kunden interessierten sich auch für
![Une perspective clinique : Analyse des mutations de l'EGFR dans les cancers primitifs du poumon]( "Une perspective clinique : Analyse des mutations de l'EGFR dans les cancers primitifs du poumon")
Une perspective clinique : Analyse des mutations de l'EGFR dans les cancers primitifs du poumon51,99 €![Lung cancer]( "Lung cancer")
Lung cancer25,99 €![Lung Cancer and Complementary Therapy]( "Lung Cancer and Complementary Therapy")
Lung Cancer and Complementary Therapy40,99 €![Statut KRAS des cancers colorectaux: étude clinico-pathologique]( "Statut KRAS des cancers colorectaux: étude clinico-pathologique")
Statut KRAS des cancers colorectaux: étude clinico-pathologique28,99 €![Prognostic value of large cell histology in lung cancer]( "Prognostic value of large cell histology in lung cancer")
Prognostic value of large cell histology in lung cancer24,99 €![The Unfolded Protein Response Pathway and Lung Cancer]( "The Unfolded Protein Response Pathway and Lung Cancer")
The Unfolded Protein Response Pathway and Lung Cancer29,99 €![Autofluorescence Imaging Bronchovideoscopy and Lung Cancer]( "Autofluorescence Imaging Bronchovideoscopy and Lung Cancer")
Autofluorescence Imaging Bronchovideoscopy and Lung Cancer47,99 €
Lung cancer, or bronchogenic carcinoma, includes malignancies originating in the airways or lung parenchyma. Key risk factors are tobacco smoking, advancing age, COPD, and exposure to carcinogens like asbestos and radon. Additionally, genetic susceptibility plays a role, with 10-15% of never-smokers developing lung cancer, often linked to a strong family history. Advances in molecular pathogenesis have shown lung cancer to be a heterogeneous disease, driven by diverse molecular abnormalities. Tumor progression is influenced by receptors like Epidermal Growth Factor Receptors (EGFR), regulated by tyrosine kinases. Targeted therapies against these mutations are now first-line treatments, while chemotherapy is used for those who fail molecular therapies. This book explores demographic and clinical factors linked to mutant TK EGFR positivity in patients with advanced-stage (IV) lung cancer, based on research from a tertiary interventional pulmonology center in Pakistan.